Back to News
Market Impact: 0.35
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Source: PR Newswire
Healthcare & BiotechProduct LaunchesRegulation & Legislation
RINVOQ received European Union approval to treat active polyarticular juvenile idiopathic arthritis in patients aged two years and older who have had an inadequate response or intolerance to one or more DMARDs. The approval, supported by open-label Phase 1 data, expands the drug's eligible patient population and provides a positive regulatory catalyst for its manufacturer.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Bitcoin rebounds to $76,000, but $1.3 billion ETF exodus tests recovery
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace